Monte Rosa Therapeutics, Inc

Internship Research Associate, Proteomics

Job Locations CH-Basel
ID
2025-1164
Category
Biomolecular Sciences
Position Type
Intern
Min
CHF 25.00/Hr.
Max
CHF 32.00/Hr.

Overview

Monte Rosa Therapeutics is seeking passionate Internship Research Associate to help us to eliminate disease causing proteins through targeted protein degradation­­–a novel and exciting way of drugging proteins that until recently were considered un-druggable­. The candidates will gain hands-on experience within a particular area of interest in an early-stage drug discovery environment. You will work with an industry leader who will direct and mentor you on your project, expose you to other drug discovery projects and involve you in solving complex biological questions. You will be joining a diverse, thoughtful, fun, and collaborative environment that emphasizes teamwork and putting people first!

 

If you have an interest in any of the following areas noted below, we will give your hands on educational experience within a high paced Drug discovery environment.

Responsibilities

  • Independently maintaining cancer cell lines in culture, e.g. splitting cells
  • Performing cell treatments and sample collection
  • Learn end execute sample preparation for LC-MS (i.e. protein digestion, TMT labeling, peptide fractionation, and instruments measurement)
  • Data Analysis and Interpretation
  • Documentation and Reporting
  • Attend and present  your data at team and project meetings.

Qualifications

  • Our preference is for a student currently in a Bachelor or Master degree (or equivalent) program in Molecular and Cell Biology, Biochemistry, or a life science.
  • Scientific desire to learn the most advanced approaches to drug discovery.
  • Biochemistry and Cell Biology centric individuals should have previous documented hands-on experience with mammalian cell culture, and preferably biochemical techniques (e.g., Western Blot).
  • Enjoys working in a team-based environment.

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed